01.01.14
OrbiMed, an investment firm focused on the healthcare sector, has closed its next venture capital fund, OrbiMed Private Investments V LP, with more than $735 million in commitments, including roughly $36 million from the general partner. Investors in the fund include some of the largest endowments, foundations, sovereign wealth funds and financial institutions globally.
Consistent with its predecessor funds, the new fund will invest in all stages and sectors of the healthcare industry, with a focus on biopharmaceutical, medical device, and diagnostics companies located in North America and Europe. The new fund is expected to invest in approximately 30 portfolio companies in amounts generally ranging from $10 million to $50 million.
“This is an exciting time to launch our next fund, given the combination of the high rate of new FDA [U.S. Food and Drug Administration] drug approvals, a vibrant IPO [initial public offering] window, and the accelerating level of innovation from companies across the life sciences investment universe,” noted Carl Gordon, a partner at OrbiMed and co-head of Global Private Equity.
“We are seeking novel healthcare innovations across biopharma, devices, diagnostics and healthcare I.T. at any stage of development,” added Jonathan Silverstein, also an OrbiMed partner and co-head of Global Private Equity. “This new fund will leverage OrbiMed’s entire global platform, which now includes more than 80 employees globally investing more than $8 billion across healthcare public equities, private equities, royalties and credit opportunities.”
OrbiMed is an investment firm dedicated exclusively to the healthcare sector, with more than $8 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team of more than 80 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York, N.Y., with additional offices in San Francisco, Calif., Shanghai, China, Mumbai, India, and Herzliya, Israel.
Consistent with its predecessor funds, the new fund will invest in all stages and sectors of the healthcare industry, with a focus on biopharmaceutical, medical device, and diagnostics companies located in North America and Europe. The new fund is expected to invest in approximately 30 portfolio companies in amounts generally ranging from $10 million to $50 million.
“This is an exciting time to launch our next fund, given the combination of the high rate of new FDA [U.S. Food and Drug Administration] drug approvals, a vibrant IPO [initial public offering] window, and the accelerating level of innovation from companies across the life sciences investment universe,” noted Carl Gordon, a partner at OrbiMed and co-head of Global Private Equity.
“We are seeking novel healthcare innovations across biopharma, devices, diagnostics and healthcare I.T. at any stage of development,” added Jonathan Silverstein, also an OrbiMed partner and co-head of Global Private Equity. “This new fund will leverage OrbiMed’s entire global platform, which now includes more than 80 employees globally investing more than $8 billion across healthcare public equities, private equities, royalties and credit opportunities.”
OrbiMed is an investment firm dedicated exclusively to the healthcare sector, with more than $8 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies. OrbiMed’s team of more than 80 employees manages a series of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York, N.Y., with additional offices in San Francisco, Calif., Shanghai, China, Mumbai, India, and Herzliya, Israel.